- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe Crohn disease; Moderate to severe ulcerative colitis; Severe active juvenile idiopathic arthritis; Complex refractory Fistulising Crohn disease; Severe active rheumatoid arthritis; Severe psoriatic arthritis; Ankylosing spondylitis; Severe chronic plaque psoriasis; Moderate to severe hidradenitis suppurativa
- Meeting Date: November 2020
- Public Summary Document (PSD) November 2020 PBAC Meeting - (PDF 818KB)
- Public Summary Document (PSD) November 2020 PBAC Meeting - (Word 39KB)
Adalimumab – November 2020
Adalimumab: Injection 40 mg in 0.8 mL pre-filled pen, Injection 40 mg in 0.8 mL pre-filled syringe, Injection 40 mg in 0.8 mL vial; Idacio®
Last updated
5 March 2021